Abstract
Most of the HIV-infected long term survivors show strong CD8+ cell noncytotoxic antiviral response (CNAR) that plays as an important factor for maintaining the relative healthy state of infected individuals. HIV infected former blood donors (FBDs) in Anhui, China are the unique population that considered infected by the same or a related HIV strain by the same exposure route, and is better to be studied for viral and host immunological factors associated with disease progression, such as CNAR. We examined CNAR in 63 asymptomatic untreated HIV infected FBDs with different CD4+ cell counts and plasma viral loads. The average CD8+ : CD4+ cell ratio to reach 90% suppression of HIV replication in the groups with CD4+ cell counts of > 500, 300-500 and < 300 cells/μl were 0.85 : 1, 1.47 : 1 and 1.88 : 1 respectively (P < 0.0001). The average CD8+ : CD4+ cell ratio to reach 90% suppression of HIV replication was 1.07 : 1 and 1.66 : 1 in the group with plasma viral load of < 30,000 and > 30,000 RNA copy/ml respectively (P=0.0002). The results indicated that CNAR activity in long-term HIV-1 infected FBDs correlates directly with CD4+ cell counts, and correlates reversely with plasma viral loads. Our findings in long term infected FBDs confirm the clinical relevancy of CNAR and suggest that CNAR could be an additional marker to help determine the optimal time for starting therapy in HIV infected person.
Keywords: HIV, CNAR, CD4+ cell count, former blood donor (FBD), long-term survivor, acute infection assay
Current HIV Research
Title: CD8+ Cell Noncytotoxic Antiviral Response in Long-Term HIV-1 Infected Former Blood Donors in China
Volume: 7 Issue: 4
Author(s): Lin Yuan, Liying Ma, Xiujuan Fan, Yi Feng, Hong Peng, Quanbi Zhao, Yuhua Ruan, J. A. Levy and Yiming Shao
Affiliation:
Keywords: HIV, CNAR, CD4+ cell count, former blood donor (FBD), long-term survivor, acute infection assay
Abstract: Most of the HIV-infected long term survivors show strong CD8+ cell noncytotoxic antiviral response (CNAR) that plays as an important factor for maintaining the relative healthy state of infected individuals. HIV infected former blood donors (FBDs) in Anhui, China are the unique population that considered infected by the same or a related HIV strain by the same exposure route, and is better to be studied for viral and host immunological factors associated with disease progression, such as CNAR. We examined CNAR in 63 asymptomatic untreated HIV infected FBDs with different CD4+ cell counts and plasma viral loads. The average CD8+ : CD4+ cell ratio to reach 90% suppression of HIV replication in the groups with CD4+ cell counts of > 500, 300-500 and < 300 cells/μl were 0.85 : 1, 1.47 : 1 and 1.88 : 1 respectively (P < 0.0001). The average CD8+ : CD4+ cell ratio to reach 90% suppression of HIV replication was 1.07 : 1 and 1.66 : 1 in the group with plasma viral load of < 30,000 and > 30,000 RNA copy/ml respectively (P=0.0002). The results indicated that CNAR activity in long-term HIV-1 infected FBDs correlates directly with CD4+ cell counts, and correlates reversely with plasma viral loads. Our findings in long term infected FBDs confirm the clinical relevancy of CNAR and suggest that CNAR could be an additional marker to help determine the optimal time for starting therapy in HIV infected person.
Export Options
About this article
Cite this article as:
Yuan Lin, Ma Liying, Fan Xiujuan, Feng Yi, Peng Hong, Zhao Quanbi, Ruan Yuhua, Levy A. J. and Shao Yiming, CD8+ Cell Noncytotoxic Antiviral Response in Long-Term HIV-1 Infected Former Blood Donors in China, Current HIV Research 2009; 7 (4) . https://dx.doi.org/10.2174/157016209788680561
DOI https://dx.doi.org/10.2174/157016209788680561 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Can Anthropometric and Body Composition Measurements During Pregnancy be Used to Predict Preeclampsia Risk?
Current Women`s Health Reviews Aldose Reductase Inhibitors and Nanodelivery of Diabetic Therapeutics
Mini-Reviews in Medicinal Chemistry Diagnosis and Prognostic Evaluation for Xerostomia Using Dynamic MR Sialography
Current Medical Imaging Pharmacological Management of Chronic Obstructive Lung Disease (COPD). Focus on Mutations - Part 1
Current Medicinal Chemistry The Role of SHP-2 in Cell Signalling and Human Disease
Current Enzyme Inhibition Effects of SORL1 Gene on Alzheimer's Disease. Focus on Gender, Neuropsychiatric Symptoms and Pro-Inflammatory Cytokines
Current Alzheimer Research Lentiviral-Mediated Gene Therapy in Fanconi Anemia-A Mice Reveals Long-Term Engraftment and Continuous Turnover of Corrected HSCs
Current Gene Therapy Anti-Tumor Monoclonal Antibodies in Conjunction with β-Glucans: A Novel Anti- Cancer Immunotherapy
Current Medicinal Chemistry Inhibitors for Metastasis Development
Recent Patents on Anti-Cancer Drug Discovery Computational Tools in the Discovery of New G-Quadruplex Ligands with Potential Anticancer Activity
Current Topics in Medicinal Chemistry Serine Proteinase Inhibitors in the Skin: Role in Homeostasis and Disease
Current Protein & Peptide Science Pharmacological Therapies for Pediatric and Neonatal ALI/ARDS: An Evidence-Based Review
Current Drug Targets NO to Breast: When, Why and Why Not?
Current Pharmaceutical Design Growth Inhibition of Human Non-Small Lung Cancer Cells H460 By Green Tea and Ginger Polyphenols
Anti-Cancer Agents in Medicinal Chemistry Direct Evidence on the Immune-Mediated Spontaneous Regression of Human Cancer: An Incentive for Pharmaceutical Companies to Develop a Novel Anti-Cancer Vaccine
Current Pharmaceutical Design Immune Disturbances in Chronic Pain: Cause, Consequence or Both?
Current Immunology Reviews (Discontinued) Novel Vaginal Drug Delivery Systems: A Review
Current Drug Therapy The Blood-Brain/Tumor Barriers: Challenges and Chances for Malignant Gliomas Targeted Drug Delivery
Current Pharmaceutical Biotechnology Intraarticular Treatments for Osteoarthritis: New Perspectives
Current Drug Targets Unsafe Abortion: The Silent Endemic; An Avoidable Cause of Maternal Mortality. A Review
Current Women`s Health Reviews